Papamichael D
Department of Medical Oncology, BOC Oncology Center, Nicosia, Cyprus.
Anticancer Res. 2001 Nov-Dec;21(6B):4349-53.
The need for dependable prognostic markers in colorectal cancer, both in the advanced as well the as adjuvant setting, is greater than ever. The introduction of new chemotherapeutic agents in the clinic, with different mechanisms of action as well as different side-effect profiles, has made this even more important. Angiogenesis, the formation of new vessels, is essential for tumour growth and metastasis. The adverse impact of tumour angiogenesis in the context of colorectal cancer on relapse and prognosis has been evaluated in numerous retrospective studies. Most of these studies have tended to be relatively small in terms of patient numbers and sometimes have reached conflicting conclusions. A number of different angiogenic factors, including vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP) and intratumoural microvessel density (IMD), have been assessed to varying extents. This article highlights some of the important developments in this rapidly expanding field.
无论是在晚期还是辅助治疗环境中，结直肠癌对可靠预后标志物的需求都比以往任何时候都更为迫切。临床中引入了具有不同作用机制和不同副作用特征的新型化疗药物，这使得这一需求变得更加重要。血管生成，即新血管的形成，对于肿瘤的生长和转移至关重要。在众多回顾性研究中，已经评估了结直肠癌背景下肿瘤血管生成对复发和预后的不利影响。这些研究中的大多数在患者数量方面往往相对较少，有时还得出了相互矛盾的结论。包括血管内皮生长因子（VEGF）、胸苷磷酸化酶（TP）和肿瘤内微血管密度（IMD）在内的多种不同血管生成因子已在不同程度上得到评估。本文重点介绍了这一迅速发展领域中的一些重要进展。
